



**UNICHEM
LABORATORIES LTD.**

August 13, 2019

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001, India
Scrip Code: 506690

**The National Stock Exchange of
India Limited**
Exchange Plaza,
Plot no. C/1, G Block
Bandra-Kurla Complex
Bandra (East)
Mumbai - 400 051, India
Symbol: UNICHEMLAB

Dear Sir,

**Intimation under Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from USFDA for Unichem's Tramadol Hydrochloride Tablets USP, 50 mg.

For Unichem Laboratories Limited

Pradeep Bhandari

Pradeep Bhandari
Head- Legal & Company Secretary





UNICHEM
LABORATORIES LTD.

Mumbai, Tuesday, August 13, 2019

PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from USFDA for Unichem's Tramadol Hydrochloride Tablets USP, 50 mg. to market a generic version of Ultram® Tablets, 50 mg, of Janssen Pharmaceuticals, Inc. which are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

The Product will be commercialized from Unichem's Ghaziabad plant.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at www.unichemlabs.com

For more information please contact:

Mr. Pradeep Bhandari

Ph: +91-22-66888 404

pradeep.bhandari@unichemlabs.com

Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

